Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study.
Xiangyang LiuLi WangYing XingSamuel S EngelLongyi ZengBin YaoWen XuGuojuan ChenYe ZhangRuya ZhangShu LiuJianping WengQiuhe JiPublished in: Journal of diabetes investigation (2020)
In elderly Chinese type 2 diabetes mellitus patients, metformin/sitagliptin-based dual and triple oral therapy can provide clinically meaningful glycemic control and is generally well tolerated with a low incidence of hypoglycemia.
Keyphrases
- glycemic control
- type diabetes
- end stage renal disease
- blood glucose
- chronic kidney disease
- newly diagnosed
- ejection fraction
- weight loss
- middle aged
- community dwelling
- insulin resistance
- peritoneal dialysis
- prognostic factors
- risk factors
- stem cells
- randomized controlled trial
- clinical trial
- adipose tissue
- metabolic syndrome
- skeletal muscle
- open label